BGI Genomics Co Ltd
300676
Company Profile
Business description
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Contact
21 Hongan Third Street
Dong
Huada Complex Park
Yantian District
Shenzhen518083
CHNT: +86 75536307065
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
3,702
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.40 | 58.90 | -0.66% |
| CAC 40 | 7,722.09 | 44.12 | -0.57% |
| DAX 40 | 24,009.38 | 50.91 | -0.21% |
| Dow JONES (US) | 44,254.78 | 231.49 | 0.53% |
| FTSE 100 | 8,926.55 | 11.77 | -0.13% |
| HKSE | 24,517.76 | 72.36 | -0.29% |
| NASDAQ | 20,730.49 | 52.69 | 0.25% |
| Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
| NZX 50 Index | 12,846.40 | 91.81 | 0.72% |
| S&P 500 | 6,263.70 | 19.94 | 0.32% |
| S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
| SSE Composite Index | 3,503.78 | 1.22 | -0.03% |